Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Topical PF-07038124 in Healthy Japanese Adults
NCT04863417Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07038124 in atopic dermatitis (AD) and plaque psoriasis (2 cohorts), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Number of Participants With Clinically Significant Changes in Vital Signs and 3 more. Started Jun 2021; status: completed.
02
Drugs
PF-07038124
03
Conditions
atopic dermatitis (AD)plaque psoriasis
Beyond the preview
Go deeper on NCT04863417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04863417.